Global epidemiology of retinal vein occlusion: a systematic review and meta-analysis of prevalence, incidence, and risk factors. Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Rogers S, McIntosh RL, Cheung N, Lim L, Wang JJ, Mitchell P, Kowalski JW, Nguyen H, Wong TY International Eye Disease Consortium. Retinal vein occlusion (RVO) guideline: executive summary. Nicholson L, Talks SJ, Amoaku W, Talks K, Sivaprasad S. Macular grid laser photocoagulation for branch retinal vein occlusion. 10-Year Framingham risk in patients with retinal vein occlusion: a systematic review and meta-analysis. Khan Z, Almeida DR, Rahim K, Belliveau MJ, Bona M, Gale J. Havens SJ, Gulati V Neovascular glaucoma. Intravitreal steroids versus observation for macular edema secondary to central retinal vein occlusion. Retinal Vein Occlusions Preferred Practice Pattern. 2014 (5):CD007325įlaxel CJ, Adelman RA, Bailey ST, Fawzi A, Lim JI, Vemulakonda GA, Ying GS. Anti-vascular endothelial growth factor for macular oedema secondary to central retinal vein occlusion. *GRADE: Grading of Recommendations Assessment, Development and Evaluation (see Sources of evidenceīraithwaite T, Nanji AA, Lindsley K, Greenberg PB. NVE and NVD likely in ischaemic occlusions) Flame haemorrhages, dot and blot haemorrhages, cotton wool spots, hard exudates, retinal oedema, and dilated tortuous veins (signs more extensive if the occlusion is ischaemic compared to a non-ischaemic BRVO.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |